Northwest Bioth Cmn (NWBO)

$0.26 +0.00 (1.65%)
Market Cap 405.51M
Revenue (ttm) 1.38M
Net Income (ttm) -83.78M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -6,071.01%
Debt to Equity Ratio 0.00
Volume 1,867,600
Avg Vol 3,407,590
Day's Range N/A - N/A
Shares Out 1.59B
Stochastic %K 28%
Beta -0.86
Analysts Strong Buy
Price Target $2.00

Company Profile

Northwest Biotherapeutics, Inc., a biotechnology company, engages in the development of personalized immune therapies for cancer. The company develops DCVax, a platform technology which uses activated dendritic cells to mobilize a patient's own immune system to attack cancer. It also engages in the development of its lead product candidate DCVax-L in Phase III trials for glioblastoma multiforme brain cancer. In addition, the company develops DCVax-Direct in Phase I trials to treat inoperable sol...

Industry: Biotechnology
Sector: Healthcare
Phone: 240 497 9024
Address:
4800 Montgomery Lane, Suite 800, Bethesda, United States
LulaBacklund753
LulaBacklund753 Aug. 5 at 9:09 AM
$NWBO $OKLO $OCGN $AVGO $LCID Northwest Biotherapeutics depends on clinical progress, Oklo advances next-generation nuclear energy, Ocugen focuses on innovative therapies, Broadcom benefits from AI networking, and Lucid continues scaling EV production.
0 · Reply
Paffus
Paffus Aug. 5 at 8:50 AM
$NWBO Soon longs whe are there💎 Cant predict the price. But its gone be significant IMO So Lfg 🦍💎🦬
0 · Reply
BunMac
BunMac Aug. 5 at 7:42 AM
$NWBO 💜🐂⚖️⏰💪🤩
0 · Reply
PeterBrenneman862
PeterBrenneman862 Aug. 5 at 6:04 AM
$NWBO $MSOS $USAR $NCLH $AEHR Northwest Biotherapeutics depends on clinical execution, MSOS provides cannabis sector exposure, USAR remains execution-driven, Norwegian Cruise Line continues improving profitability, and Aehr Test benefits from semiconductor testing demand.
0 · Reply
WillyWanger
WillyWanger Aug. 5 at 4:27 AM
$NWBO good to see Andy Burnham involved. Hopefully can push the treatments that actually work. That’s why there was no DcVax mention
1 · Reply
yensid
yensid Aug. 5 at 1:57 AM
$NWBO https://x.com/hollensbeamanda/status/2084774082092888567?s=61
0 · Reply
BonGirl
BonGirl Aug. 5 at 1:21 AM
$NWBO
0 · Reply
None_
None_ Aug. 5 at 12:57 AM
$NWBO This trend benefiting placebo extends to subgroups. We know the mOS from surgery of MGMT+ patients was 35.1 months blended. With 3.1 months reported between surgery and randomization that equates to 32 months blended (2:1 randomization). The Zoom call reported the DCVax-L MGMT+ patients did 30.2 months. So that would be about 30.2 for DCVax-L vs. 35.6 months for placebo. Similarly for MGMT- patients we see 16.7 months blended. For DCVax-L MGMT- it was reported at 14.9 months. So, 14.9 for DCVax-L vs. 20.3 for placebo. How do you keep investors interested? You divert attention from the failure and use historical controls! Look at this shiny object over here!
2 · Reply
None_
None_ Aug. 5 at 12:54 AM
$NWBO The trend was not positive for DCVax-L, the trend was towards harm. That is true for both PFS, and likely OS. In addition to the median (23.1 months blended, 22.4 months DCVax-L), another OS data point is 36 month landmark survival. For the blended population, the 36 month survival was 28.2% (2018 Liau presentation). For the DCVax-L arm the 36 month survival was 20.2% (Zoom 2022 meeting). Yes, one was from surgery and the other from randomization three months later, but the trend to harm in ITT survival for DCVax-L is undeniable. I'll take that a step further, with an OS HR of 1.09 (mOS for placebo 24.5 months vs. DCVax-L 22.4 months), 2:1 randomization and assuming proportional hazards, the p-value on OS would be stat sig with 280 events. That is stat sig favoring placebo. If not, we can say, at the least, a strong trend favoring placebo was observed. Yeah, something tells me they're not going to show the OS data!
0 · Reply
None_
None_ Aug. 5 at 12:44 AM
$NWBO It would be nice if @Stocktwits could stop posts like this, which not only add nothing, but also alter the sentiment meter.
0 · Reply
Latest News on NWBO
No data available.
LulaBacklund753
LulaBacklund753 Aug. 5 at 9:09 AM
$NWBO $OKLO $OCGN $AVGO $LCID Northwest Biotherapeutics depends on clinical progress, Oklo advances next-generation nuclear energy, Ocugen focuses on innovative therapies, Broadcom benefits from AI networking, and Lucid continues scaling EV production.
0 · Reply
Paffus
Paffus Aug. 5 at 8:50 AM
$NWBO Soon longs whe are there💎 Cant predict the price. But its gone be significant IMO So Lfg 🦍💎🦬
0 · Reply
BunMac
BunMac Aug. 5 at 7:42 AM
$NWBO 💜🐂⚖️⏰💪🤩
0 · Reply
PeterBrenneman862
PeterBrenneman862 Aug. 5 at 6:04 AM
$NWBO $MSOS $USAR $NCLH $AEHR Northwest Biotherapeutics depends on clinical execution, MSOS provides cannabis sector exposure, USAR remains execution-driven, Norwegian Cruise Line continues improving profitability, and Aehr Test benefits from semiconductor testing demand.
0 · Reply
WillyWanger
WillyWanger Aug. 5 at 4:27 AM
$NWBO good to see Andy Burnham involved. Hopefully can push the treatments that actually work. That’s why there was no DcVax mention
1 · Reply
yensid
yensid Aug. 5 at 1:57 AM
$NWBO https://x.com/hollensbeamanda/status/2084774082092888567?s=61
0 · Reply
BonGirl
BonGirl Aug. 5 at 1:21 AM
$NWBO
0 · Reply
None_
None_ Aug. 5 at 12:57 AM
$NWBO This trend benefiting placebo extends to subgroups. We know the mOS from surgery of MGMT+ patients was 35.1 months blended. With 3.1 months reported between surgery and randomization that equates to 32 months blended (2:1 randomization). The Zoom call reported the DCVax-L MGMT+ patients did 30.2 months. So that would be about 30.2 for DCVax-L vs. 35.6 months for placebo. Similarly for MGMT- patients we see 16.7 months blended. For DCVax-L MGMT- it was reported at 14.9 months. So, 14.9 for DCVax-L vs. 20.3 for placebo. How do you keep investors interested? You divert attention from the failure and use historical controls! Look at this shiny object over here!
2 · Reply
None_
None_ Aug. 5 at 12:54 AM
$NWBO The trend was not positive for DCVax-L, the trend was towards harm. That is true for both PFS, and likely OS. In addition to the median (23.1 months blended, 22.4 months DCVax-L), another OS data point is 36 month landmark survival. For the blended population, the 36 month survival was 28.2% (2018 Liau presentation). For the DCVax-L arm the 36 month survival was 20.2% (Zoom 2022 meeting). Yes, one was from surgery and the other from randomization three months later, but the trend to harm in ITT survival for DCVax-L is undeniable. I'll take that a step further, with an OS HR of 1.09 (mOS for placebo 24.5 months vs. DCVax-L 22.4 months), 2:1 randomization and assuming proportional hazards, the p-value on OS would be stat sig with 280 events. That is stat sig favoring placebo. If not, we can say, at the least, a strong trend favoring placebo was observed. Yeah, something tells me they're not going to show the OS data!
0 · Reply
None_
None_ Aug. 5 at 12:44 AM
$NWBO It would be nice if @Stocktwits could stop posts like this, which not only add nothing, but also alter the sentiment meter.
0 · Reply
None_
None_ Aug. 5 at 12:40 AM
$NWBO The shame is presenting a negative trial as though it was a success. The goal of clinical research is to find new effective treatments for patients. It is not to make corporate executives more wealthy. Also, DCVax-L was tested with SOC, which includes both radiotherapy and chemotherapy.
0 · Reply
Bajamike
Bajamike Aug. 4 at 11:35 PM
$NWBO Interesting that ST started adding after hours when no trades have taken place ...who knows ? ​$0.00 (0.00%) After Hours
2 · Reply
ShartMaster7
ShartMaster7 Aug. 4 at 10:46 PM
$NWBO UK Prime Minister Andy Burnham responded! https://www.bbc.co.uk/sport/articles/c5y4pp7q1wko
3 · Reply
ILuvbiotech
ILuvbiotech Aug. 4 at 10:42 PM
$NWBO I really do pray this becomes a reality 🤲
2 · Reply
sDinvestments1
sDinvestments1 Aug. 4 at 7:55 PM
$NWBO I really hope that Linda’s intuition (gut feel indicator) has improved since the last time she made a $50 mill standby option availble. It was never tapped on the first go around when she likely felt we were in a window where it would be advantageous to have it ready at a moments notice, and now its renewed again and available to snag if needed and it will be needed. Window could be weeks or could be months. I’d really appreciate not having all our eggs in just one shitty basket (mhra’s hands) Its past time to apply elsewhere and get the ball rolling. Need proactive efforts as badly as we need cash and approval.
0 · Reply
robtown
robtown Aug. 4 at 7:41 PM
$NWBO I manage to buy at HOD every day.
1 · Reply
Jeff226
Jeff226 Aug. 4 at 6:30 PM
$NWBO It has been like premeditated murder for over a year! All for what, BP chemo, radiation, and the suffering of using these treatments is pure torture! Good job regulators, the opportunity to save lives has turned into blood on your hands! The treatment would not have harmed anyone, all it would do is help!
2 · Reply
Jjscans
Jjscans Aug. 4 at 6:27 PM
$NWBO
0 · Reply
lwheeler
lwheeler Aug. 4 at 5:19 PM
$NWBO
0 · Reply
yensid
yensid Aug. 4 at 4:43 PM
$NWBO https://x.com/allairemar73316/status/2084624903009960389?s=61
2 · Reply
ExploringTrades
ExploringTrades Aug. 4 at 4:08 PM
Ticker NEXR has barely 550,000 shares outstanding. The only comparable ticker was VEEE and that one ran from 4.10$ to over 51$. NEXR released news on Aug 3rd and is shifting heavily into the AI sector. NEXR has only about 700 watchers on Stocktwits. Took a big position looking to profit massively very soon. $AKAN $NWBO good buls here
0 · Reply
Paraplego
Paraplego Aug. 4 at 3:52 PM
$NWBO is waiting game and im fine with it while im waiting im investing in $PLYX 14th Avgust is close for News and some small gains
0 · Reply